This overview page provides a quick summary of the selected assets, including their latest prices, price changes, market capitalization changes, and more.
This page just gave you an overview, you might also want to check out the comprehensive stats, historical, correlation, volatility, and price projection pages.
ADC Therapeutics S.A. is a commercial-stage biotechnology company focused on the development and commercialization of novel antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Operating within the oncology sector, the company leverages its proprietary ADC technology platform to create highly potent and targeted cancer therapies. The company's lead product, Zynlonta (loncastuximab tesirine-lpyl), is approved in the United States for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. ADC Therapeutics has a robust pipeline of ADCs in various stages of clinical development, targeting a range of cancers. Its strategic focus on unmet medical needs in oncology positions it as a key player in the rapidly evolving field of targeted cancer therapeutics. The company's innovative approach aims to improve patient outcomes by delivering potent cytotoxic agents directly to cancer cells, minimizing systemic toxicity.
Read moreThis website uses cookies for essential functions, other functions, and for statistical purposes. Please refer to the cookie policy for details.
This feature requires functional cookies. Please refer to the cookie policy for details.
We sent you a verification email. Copy and paste the verification code above.
Trade hundreds of crypto perpetual futures